TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24401940
Drug: Maxalt (10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxalt (10‐mg rizatriptan)
Study: 20443650
Drug: Olopatadine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 5 mg
Study: 20443650
Drug: Olopatadine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 2.5 mg
Study: 17588581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other antihypertensive treatment)
Study: 16805936
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg‐1 h‐1
Study: 10690672
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg rectally 3 times during the first 24 hours postoperatively
Study: 9374256
Drug: Heparin-coated IOLs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated IOLs
Study: 8263310
Drug: d-fenfluramine and
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine and d-amphetamine combination
Study: 3834831
Drug: Rimantadine hydrochloride
Normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimantadine hydrochloride (200 mg single dose)
Study: 3834831
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride (200 mg single dose)
Study: 24774470
Drug: Tailor‐made weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailor‐made weight loss intervention and oral glucosamine sulfate
Study: 19926502
Drug: Prednisone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (25 mg daily for 15 days, then 12.5 mg daily for 15 days, then 6.25 mg daily for 15 days, then 6.25 mg on alternate days for 15 days)
Study: 19926502
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg daily for the first month, then on alternate days for the second month)
Study: 19926502
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg cellulose daily for the first month, then on alternate days for the second month)
Study: 19061737
Drug: Low-frequency electric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency electric muscle stimulation combined with conventional physical therapy (n=16; 78±8 y)
Study: 19061737
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy alone (n=13; 76±10 y)
Study: 8676836
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (LBA) treatment
Study: 4003917
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) aerosol, 4 inhalations twice a day (b.i.d.), total dose 336 micrograms/day for 8 weeks
Study: 4003917
Drug: Placebo aerosol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol, 4 inhalations twice a day (b.i.d.) for 8 weeks
Study: 4003917
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) aerosol, 2 inhalations 4 times a day (q.i.d.), total dose 336 micrograms/day for 2 weeks
Study: 20373168
Drug: Family medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family medicine clerkship with a 3-hour workshop on clinical reasoning using illness scripts.
Study: 15034161
Drug: Ketoconazole 100
Normalized name: ketoconazole 100 % MISCELL CRYSTALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 100 mg/day in addition to tacrolimus
Study: 7614594
Drug: dietetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: dietetic therapy of chinese herb rhizome wheat starch
Study: 3277325
Drug: Definitive radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiation therapy with additional cyclophosphamide (Cytoxan) or estramustine phosphate (Emcyt) chemotherapy for 2 years
Study: 3277325
Drug: Definitive radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiation therapy only
Study: 22899947
Drug: Transamidated gluten
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transamidated gluten (3.7 g/day)
Study: 19865058
Drug: EPO (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron
Study: 19865058
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron only
Study: 9529266
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens therapy at 0.625 mg daily
Study: 2388978
Drug: Dextrose tablets
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose tablets
Study: 2388978
Drug: Sorbitol tablets
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol tablets (control)
Study: 832943
Drug: Undecylenic acid
Normalized name: Undecylenic Acid
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undecylenic acid powder preparations
Study: 31820289
Drug: Ibudilast (IBUD)
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ibudilast (IBUD) 50 mg twice daily for 12 weeks
Study: 28658112
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg propofol (LPE group)
Study: 28658112
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg propofol (MPE group)
Study: 28658112
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg propofol (HPE group)
Study: 28658112
Drug: 1 to
Normalized name: Cep-11981 tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 mg/kg propofol (P group)
Study: 28658112
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg propofol (E group)
Study: 21368386
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2 mg/d
Study: 21368386
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 10 mg/d
Study: 19267739
Drug: Chemotherapy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy at a community hospital
Study: 19267739
Drug: Chemotherapy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy at a cancer centre
Study: 3345643
Drug: Sucralfate (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1-g tablet, four times a day for two days before and after theophylline dose)
Study: 3345643
Drug: Non-sustained-release theophylline
Normalized name: theophylline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-sustained-release theophylline (5-mg/kg dose)
Study: 25966723
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus metronidazole and amoxicillin (M+A group)
Study: 23149171
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency defined as 25(OH)D level <20 ng/mL
Study: 15201620
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy with LDL-c level < 100 mg/dl
Study: 15201620
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy with LDL-c level > 100 mg/dl
Study: 8042971
Drug: Treatment (comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (comprehensive relapse prevention program)
Study: 3076905
Drug: Amitriptyline (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (median dose 125 mg)
Study: 21732834
Drug: Isoniazid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (10 to 20 mg per kilogram of body weight per day)
Study: 1577361
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg haloperidol/day for 14 days
Study: 1577361
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg haloperidol/day for 14 days
Study: 3453428
Drug: Individually adapted
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually adapted haloperidol dose for 14 days
Study: 3453428
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment (10 mg or 20 mg haloperidol)
Study: 31605794
Drug: Pembrolizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (100 to 200 mg every 3 weeks for up to 16 cycles)
Study: 26062091
Drug: Conventional drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drop of fluorescein solution (20 mg/mL) administered to the right eye
Study: 26062091
Drug: Ocular mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular mist (10 μL) of fluorescein solution (20 mg/mL) applied to the left eye
Study: 12826988
Drug: Diphenhydramine 75
Normalized name: diphenhydramine 18.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 75 mg
Study: 11182260
Drug: PharmChek sweat
Approvals — FDA: no, EMA: no, PMDA: no
Description: PharmChek sweat patch
Study: 7942084
Drug: Gonadotropin releasing
Normalized name: Gonadotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin releasing hormone analog plus gonadotropins (group B)
Study: 7942084
Drug: Gonadotropins only
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropins only (group A) with low progesterone levels (< or = 1 ng/ml)
Study: 3061183
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. over 4-8 weeks
Study: 25488826
Drug: Low 25(OH)D
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low 25(OH)D metabolism score
Study: 17021422
Drug: Milk (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (300 ml)
Study: 8106650
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg once daily for 6 weeks)
Study: 8106650
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg once daily for 6 weeks)
Study: 3492156
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of propofol at 54 micrograms X kg‐1 X min‐1 (group 1)
Study: 3492156
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of propofol at 108 micrograms X kg‐1 X min‐1 (group 2)
Study: 19134170
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and counselling arms split into two groups to explore different treatment regimens
Study: 11369685
Drug: Short oral
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short oral anticoagulant course (3 months for P-DVT/PE; 6 weeks for C-DVT)
Study: 11369685
Drug: Long oral
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long oral anticoagulant course (6 months for P-DVT/PE; 12 weeks for C-DVT)
Study: 11369685
Drug: Short oral
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short oral anticoagulant course
Study: 11369685
Drug: Long oral
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long oral anticoagulant course
Study: 9272331
Drug: Whole-cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis vaccines
Study: 2890669
Drug: Bucindolol 100
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 100 mg/d
Study: 2890669
Drug: Bucindolol 200
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 200 mg/d
Study: 2890669
Drug: Bucindolol 300
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 300 mg/d
Study: 6379505
Drug: Propranolol 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 320 mg/d
Study: 30103679
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (1 mcg/Kg bolus followed by 1 mcg/Kg/hour for 90 min)
Study: 30103679
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (Control group)
Study: 26718688
Drug: RVF MP‐12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVF MP‐12, administered subcutaneously (SQ) at a concentration of 10(4.7) plaque‐forming units (pfu)
Study: 26718688
Drug: RVF MP‐12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVF MP‐12, administered intramuscularly (IM) at 10(3.4) pfu (IM Group 1)
Study: 26718688
Drug: RVF MP‐12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVF MP‐12, administered IM at 10(4.4) pfu (IM Group 2)
Study: 22965404
Drug: Colonic irrigation
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic irrigation and oral antibiotics (1 L of tap water daily and a 1-week course of ciprofloxacin and metronidazole)
Study: 20944503
Drug: d-amphetamine (8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (8, 16, and 24 mg)
Study: 20944503
Drug: d-amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0, 8, 16, and 24 mg)
Study: 18977988
Drug: Prophylaxis (co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis (co-trimoxazole 15 mg/kg per day or co-amoxiclav 15 mg/kg per day for 12 months)
Study: 16443054
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.3%
Study: 10518234
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 intramuscular methotrexate on day 1
Study: 10518234
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 intramuscular methotrexate followed by 800 micrograms vaginal misoprostol 3 days later
Study: 7898846
Drug: Low-dose monophasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monophasic oral contraceptives (OCs)
Study: 7898846
Drug: No OCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No OCs or other hormonally active medications
Study: 1456487
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with wheat flour
Study: 6697889
Drug: Timed-release tablet
Normalized name: RITE AID Natural Vitamin B-12 1000mcg Timed-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-release tablet containing carbinoxamine maleate 8 mg and pseudoephedrine hydrochloride 120 mg
Study: 6697889
Drug: Timed-release tablet
Normalized name: RITE AID Natural Vitamin B-12 1000mcg Timed-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-release tablet
Study: 17250613
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 1,200 mg)
Study: 15748221
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hyperhomocysteinemia
Study: 9682390
Drug: SB DTaP
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB DTaP vaccine
Study: 9682390
Drug: CB DTaP
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB DTaP vaccine
Study: 7800902
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg p.o. plus metoclopramide 10 mg p.o. (metoclopramide group, n = 322)
Study: 7800902
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg p.o. (control group, n = 315)
Study: 3153710
Drug: Yohimbine (YOH)
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (YOH) 0.8 mg/kg
Study: 2878812
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZ) 0.3 mg/kg
Study: 31822251
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (doses not specified)
Study: 29182412
Drug: Water loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water loading (100 ml/kg for Days 1-3, 15 ml/kg on Day 4)
Study: 26248357
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cadazolid BID
Study: 26248357
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cadazolid BID
Study: 26248357
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg cadazolid BID
Study: 26248357
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg vancomycin QID
Study: 23347400
Drug: Ultra-low-dose vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose vaginal estriol 0.03 mg in combination with Lactobacillus acidophilus KS400 (Gynoflor(®) vaginal tablets)
Study: 23347400
Drug: Ultra-low-dose vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose vaginal estriol 0.03 mg in combination with Lactobacillus acidophilus KS400 (Gynoflor(®) vaginal tablets) during maintenance therapy
Study: 18226399
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) during hemodialysis
Study: 16606393
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fluoroscopy regime
Study: 8772759
Drug: Propafenone 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 750 mg/day for 48 hours before cardioversion
Study: 1408320
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg, orally)
Study: 1408320
Drug: Antipyrine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine (1000 mg, orally)
Study: 3892996
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin 100 mg
Study: 31533906
Drug: Patiromer (8·4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (8·4 g once daily)
Study: 3946771
Drug: Hyoscine patch
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine patch
Study: 27385502
Drug: Topical high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical high-dose combination of clonidine (0.1%) + pentoxifylline (5%)
Study: 27385502
Drug: Topical low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical low-dose combination of clonidine (0.04%) + pentoxifylline (2%)
Study: 27385502
Drug: Placebo treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatments for both low-dose and high-dose combinations
Study: 27385502
Drug: High-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combination of clonidine + pentoxifylline
Study: 15892287
Drug: Qingyuan decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingyuan decoction combined with antibiotics
Study: 10428519
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin daily for > or = 14 days
Study: 2298828
Drug: Nimodipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (2 mg/h constant i.v. infusion for 5 days, 120 mg/day orally for another 16 days)
Study: 12085574
Drug: Glass syringes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass syringes with daily new needles
Study: 31683132
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation (PMR) and music therapy
Study: 26467764
Drug: 12 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 sessions of aerobic exercise at preferred intensity alongside treatment as usual
Study: 26467764
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual only
Study: 23300303
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis PB6 at 500 g/t of feed, containing 5 × 10(11) cfu/kg
Study: 11494935
Drug: Antidepressant prescribing
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant prescribing practices by nurse practitioners
Study: 9269644
Drug: Amino/Bic (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino/Bic (1% amino acid, 34 mmol/l bicarbonate)
Study: 9269644
Drug: Glu/Bic (1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glu/Bic (1.5% glucose, 34 mmol/l bicarbonate)
Study: 9269644
Drug: Glu/Lac (1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glu/Lac (1.5% glucose, 35 mmol/l lactate)
Study: 3126508
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g l-carnitine (endovenous)
Study: 25985369
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (eccentric exercise regime under physiotherapeutic supervision)
Study: 25034509
Drug: Rectal NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal NSAID
Study: 15970918
Drug: Around-the-clock (ATC)
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Around-the-clock (ATC) dosing of acetaminophen with codeine
Study: 15970918
Drug: As-needed (PRN)
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As-needed (PRN) dosing of acetaminophen with codeine
Study: 12775122
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g MCT (10M)